WHIM Syndrome Management: The First FDA Approval for Patients
Teresa K. Tarrant, MD
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
Yelena Janjigian, MD
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.